Business & regional news

Month Year

Month Year

Oct 11, 2024

Medtronic announces FDA approval for early feasibility trial of Affera™ Mapping and Ablation System with Sphere-9™ Catheter for the treatment of ventricular tachycardia

The VT research will provide important clinical evidence in an underserved patient population
- Cardiac Ablation Solutions
Aug 22, 2024

First enrollment completed in REAL-Pulse, PulseSelect™ pulsed field ablation system global registry, as demand and adoption continue to increase

Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile
- Cardiac Ablation Solutions
May 10, 2024

PulseSelect™ pulsed field ablation system receives approval in Japan, broadening global impact of paradigm-shifting AFib treatment
- Cardiac Ablation Solutions
Feb 1, 2024

Medtronic announces successful first cases using PulseSelect™ pulsed field ablation system

Physician feedback confirms clinical evidence: safe, efficient, and effective treatment offers most versatile new option for atrial fibrillation
- Cardiac Ablation Solutions
Nov 20, 2023

Medtronic receives CE Mark Approval for innovative technologies in pulsed field and cryoablation: PulseSelect™ Pulsed Field Ablation System and Nitron CryoConsole™ to advance treatment of atrial fibrillation

Simplicity, efficiency, efficacy with unmatched safety data to set a new standard in catheter ablation
- Cardiac Ablation Solutions
May 19, 2023

Medtronic PulseSelect Pulsed Field Ablation System Results in Low Atrial Arrhythmia Burden for AFib Patients

Heart Rhythm 2023: Late-breaking analysis of the PULSED AF Trial reveals first of its kind significant, meaningful quality of life improvements and healthcare utilization benefits of the PulseSelect Pulsed Field Ablation System
- Cardiac Ablation Solutions
- Photos 1
Apr 16, 2023

Novel Medtronic Affera™ Mapping and Ablation System with the Sphere-9™ Catheter Demonstrates Safety and Performance for the Treatment of Atrial Fibrillation

12-month results reinforce versatility and durability for the treatment of paroxysmal and persistent AFib with the first-of-its-kind pulsed field ablation, radiofrequency, and high density mapping Sphere-9™ Catheter
- Cardiac Ablation Solutions
Nov 7, 2022

The New England Journal of Medicine: 36-month data demonstrate that Medtronic cryoablation significantly reduces atrial fibrillation disease progression and is a superior initial treatment compared to drug therapy
- Cardiac Ablation Solutions
Apr 27, 2022

Medtronic to acquire Acutus Medical left-heart access portfolio

Medtronic today announced that it has signed an agreement with Acutus Medical Inc., a manufacturer of arrhythmia management technologies, for exclusive rights to distribute and acquire its...
- Cardiac Ablation Solutions

Show per page